You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm will use the funds to build inventory to meet anticipated demand, expand its sales and marketing efforts, and for general corporate purposes.
The loan will help fund Scope's development of its PCR One point-of-care molecular diagnostic instrument and related respiratory virus panel.
The company's contract with the NIH offered $12 million total and after initial test verification, Fluidigm will receive approximately $11 million.
Fluidigm's Advanta Dx SARS-CoV-2 RT-PCR assay is an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus.
The firm's $42.9 million in total revenues and $.41 loss per share for the second quarter both beat the average analyst estimates.
In Q2 the firm filed for FDA Emergency Use Authorization for its saliva-based Advanta Sx SARS-CoV-2 RT-PCR assay as it continued its pivot to COVID-19 markets.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.
Codefendant 1Cellbio, an instrument maker that had obtained a co-exclusive license to the patents, said it plans to appeal the court's declaration.
AbCellera claims that Berkeley Lights is infringing on eight patents related to the use of microfluidics, genomic sequencing, and other methods.
Irvine, California-based Fluxergy is working with the MGB Center for COVID Innovation to evaluate the firm's research-use-only COVID-19 testing platform.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.